The Claim
In older adults with ischemic systolic heart failure, daily administration of 10 mg rosuvastatin does not increase the incidence of muscle-related adverse events, liver enzyme elevations, or renal dysfunction compared to placebo.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In older adults with a specific type of heart failure, taking 10 mg of rosuvastatin every day does not lead to higher rates of muscle problems, liver enzyme increases, or kidney dysfunction compared to taking a placebo.
See the scientific wording
In older adults with ischemic systolic heart failure, daily 10 mg rosuvastatin does not increase the risk of muscle-related adverse events, liver enzyme elevations, or renal dysfunction compared to placebo, despite theoretical concerns about statin-induced myopathy and reduced coenzyme Q10 synthesis.
Rosuvastatin blocks a key enzyme in the liver that makes cholesterol, which also lowers the production of molecules that trigger inflammation and stress in blood vessels. This reduces inflammation markers and protects blood vessels without harming muscle, liver, or kidney cells, even in older people with heart failure.
What the research says
1 studyStudy: Rosuvastatin in older patients with systolic heart failure.
In older heart failure patients, taking rosuvastatin daily didn't cause more muscle pain, liver issues, or kidney problems than taking a sugar pill, even though doctors were worried it might. The study checked carefully and found no extra side effects.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.